Literature DB >> 26484747

Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.

Wilhelmus E A de Witte1, Yin Cheong Wong1, Indira Nederpelt2, Laura H Heitman2, Meindert Danhof1, Piet H van der Graaf1, Ron A H J Gilissen3, Elizabeth C M de Lange1.   

Abstract

INTRODUCTION: Drug-target binding kinetics are major determinants of the time course of drug action for several drugs, as clearly described for the irreversible binders omeprazole and aspirin. This supports the increasing interest to incorporate newly developed high-throughput assays for drug-target binding kinetics in drug discovery. A meaningful application of in vitro drug-target binding kinetics in drug discovery requires insight into the relation between in vivo drug effect and in vitro measured drug-target binding kinetics. AREAS COVERED: In this review, the authors discuss both the relation between in vitro and in vivo measured binding kinetics and the relation between in vivo binding kinetics, target occupancy and effect profiles. EXPERT OPINION: More scientific evidence is required for the rational selection and development of drug-candidates on the basis of in vitro estimates of drug-target binding kinetics. To elucidate the value of in vitro binding kinetics measurements, it is necessary to obtain information on system-specific properties which influence the kinetics of target occupancy and drug effect. Mathematical integration of this information enables the identification of drug-specific properties which lead to optimal target occupancy and drug effect in patients.

Entities:  

Keywords:  PKPD modeling; drug-target binding kinetics; endogenous competition; in vitro; in vivo; mechanistic; nonspecific binding; patients; rebinding; target turnover

Mesh:

Substances:

Year:  2015        PMID: 26484747     DOI: 10.1517/17460441.2016.1100163

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  12 in total

1.  The Added Value of Assessing Ligand-Receptor Binding Kinetics in Drug Discovery.

Authors:  Dong Guo; Laura H Heitman; Adriaan P IJzerman
Journal:  ACS Med Chem Lett       Date:  2016-08-19       Impact factor: 4.345

2.  Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2017-10-18       Impact factor: 8.739

Review 3.  Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.

Authors:  Yumi Yamamoto; Meindert Danhof; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-03-09       Impact factor: 4.009

4.  Using mathematical modeling to estimate time-independent cancer chemotherapy efficacy parameters.

Authors:  Christine Pho; Madison Frieler; Giri R Akkaraju; Anton V Naumov; Hana M Dobrovolny
Journal:  In Silico Pharmacol       Date:  2021-12-05

5.  Drug-Target Kinetics in Drug Discovery.

Authors:  Peter J Tonge
Journal:  ACS Chem Neurosci       Date:  2017-07-14       Impact factor: 4.418

Review 6.  Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease.

Authors:  Alok Joshi; Da-Hui Wang; Steven Watterson; Paula L McClean; Chandan K Behera; Trevor Sharp; KongFatt Wong-Lin
Journal:  Neuropharmacology       Date:  2020-05-04       Impact factor: 5.250

7.  In vitro and in silico analysis of the effects of D2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations.

Authors:  Wilhelmus E A de Witte; Joost W Versfelt; Maria Kuzikov; Solene Rolland; Victoria Georgi; Philip Gribbon; Sheraz Gul; Dymphy Huntjens; Piet Hein van der Graaf; Meindert Danhof; Amaury Fernández-Montalván; Gesa Witt; Elizabeth C M de Lange
Journal:  Br J Pharmacol       Date:  2018-09-21       Impact factor: 8.739

Review 8.  Binding kinetics of ligands acting at GPCRs.

Authors:  David A Sykes; Leigh A Stoddart; Laura E Kilpatrick; Stephen J Hill
Journal:  Mol Cell Endocrinol       Date:  2019-02-08       Impact factor: 4.102

9.  Unified Software Solution for Efficient SPR Data Analysis in Drug Research.

Authors:  Göran Dahl; Stephan Steigele; Per Hillertz; Anna Tigerström; Anders Egnéus; Alexander Mehrle; Martin Ginkel; Fredrik Edfeldt; Geoff Holdgate; Nichole O'Connell; Bernd Kappler; Annette Brodte; Philip B Rawlins; Gareth Davies; Eva-Lotta Westberg; Rutger H A Folmer; Stephan Heyse
Journal:  SLAS Discov       Date:  2016-10-28       Impact factor: 3.341

10.  Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.

Authors:  Wilhelmus E A de Witte; Vivi Rottschäfer; Meindert Danhof; Piet H van der Graaf; Lambertus A Peletier; Elizabeth C M de Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-05-18       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.